Abnormalities in protein kinase A (PKA) and Rap1 have recently been reported in depressed patients. The aim of the present study was to investigate the levels of these proteins in platelets from untreated unipolar and bipolar depressed patients with psychotic features. The levels PKA and Rap1 were assessed by Western blot analysis and immunostaining in 37 drug-free patients and 29 healthy subjects. Both unipolar and bipolar patients with psychotic depression have significantly lower levels of platelet regulatory type I and higher levels of catalytic subunits of PKA than controls, whereas the levels of regulatory type II were higher only in psychotic unipolar patients. No significant differences were found in the immunolabeling of both Rap1 and actin among groups. These findings support the idea that besides nonpsychotic depression, abnormalities of PKA could be linked, albeit in a somewhat different way, with psychotic depression. Molecular Psychiatry ( Several studies have shown that dysfunctions in PKA and some of its subtrates such as CREB and Rap1 are associated with affective disorders. [1] [2] [3] [4] [5] [6] [7] [8] [9] Delusional or psychotic depression is a severe disorder affecting approximately 20% of depressed patients and 0.6% of the general population.
Several studies have shown that dysfunctions in PKA and some of its subtrates such as CREB and Rap1 are associated with affective disorders. [1] [2] [3] [4] [5] [6] [7] [8] [9] Delusional or psychotic depression is a severe disorder affecting approximately 20% of depressed patients and 0.6% of the general population. 10 According to DSM-IV criteria, it is defined by the presence of a major depressive episode accompanied by delusions and/or hallucinations that occurs in patients suffering from unipolar or bipolar disorder. 11 Although several biological differences were reported between psychotic and nonpsychotic depression, [12] [13] [14] [15] [16] there is at present no information on the possible involvement of the cAMP signaling pathway in psychotic depression. In this study we examined the levels of PKA and Rap1 in platelets from drugfree psychotic depressed patients and healthy subjects. We demonstrated that both unipolar and bipolar patients with psychotic depression have significantly lower levels of regulatory type I and higher levels of catalytic subunits of PKA than controls, whereas the levels of regulatory type II were higher only in unipolar patients. No significant differences were found in the immunolabeling of both Rap1 and actin among groups.
These findings further support the idea that besides nonpsychotic depression, abnormalities of cAMP signaling pathway could be linked, albeit in a somewhat different way, with psychotic depression. The PKA subunits, Rap1 and actin were assessed by Western blot analysis, immunostaining and computerassisted imaging in whole platelet proteins from 37 drug-free depressed patients with psychotic features and 29 healthy subjects. Figure 1 illustrates representative immunoblots of regulatory type I (RI), type II (RII) and catalytic (C) subunits of PKA, Rap1 and actin in platelets from bipolar and unipolar patients with psychotic features and control subjects.
As determined by the analysis of variance, the immunolabeling of the RI subunit of PKA was significantly different among groups (F 2,61 = 5.90; P = 0.004). Post hoc comparisons showed that both bipolar and unipolar patients with psychotic depression had significantly lower (P Ͻ 0.01 and P Ͻ 0.05, respectively) immunolabeling of RI when compared to healthy subjects ( Figure 2) .
The ANOVA revealed significant differences also in the levels of the RII subunit of the enzyme among groups (F 2,62 = 4.40; P = 0.016). According to post hoc Figure 1 Representative immunoblots of regulatory type I (RI), type II (RII) and catalytic (C) subunits of PKA, Rap1 and actin immunoreactivity in pooled platelet proteins (standard), control subjects, and psychotic major depressed bipolar and unipolar patients. Western blot analysis was performed as described in Methods. MW indicates the apparent molecular weight.
Figure 2
Immunoreactivity of PKA RI subunit in platelets of psychotic major depressed bipolar and unipolar patients, and control subjects. Data are expressed as densitometry units normalized against those from a pooled platelet standard as described in Methods. *P Ͻ 0.01 vs controls. **P Ͻ 0.05 vs controls.
comparisons, while unipolar patients had a significant increase in the levels of this subunit compared to controls (P Ͻ 0.05), bipolar patients showed an increase that did not reach statistical significance (P = 0.08) ( Figure 3 ).
As shown in Figure 4 , significant differences were found in the immunolabeling of the C subunit of PKA (F 2,60 = 6.36; P = 0.003). Post hoc comparison indicated that bipolar and unipolar patients had greater immunolabeling of the C subunit than healthy volunteers: bipolar patients vs controls, P Ͻ 0.001; unipolar patients vs controls, P Ͻ 0.05.
The analysis of variance revealed no significant difference in the levels of Rap1 (F 2,61 = 0.78; P = 0.464) and actin (F 2,63 = 0.20; P = 0.818), a cytoskeletal protein used as internal control, among the three groups.
The main finding of the present study is that protein kinase A is altered in platelets from drug-free patients with psychotic depression. To the best of our knowledge, this is the first report showing a connection between proteins involved in cAMP signaling and psychotic depression.
Figure 3
Immunoreactivity of PKA RII subunit in platelets of psychotic major depressed bipolar and unipolar patients, and control subjects. Data are expressed as densitometry units normalized against those from a pooled platelet standard as described in Methods. *P Ͻ 0.05.
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Figure 4
Immunoreactivity of PKA catalytic subunit in platelets of psychotic major depressed bipolar and unipolar patients, and control subjects. Data are expressed as densitometry units normalized against those from a pooled platelet standard as described in Methods. *P Ͻ 0.01 vs controls. **P Ͻ 0.05 vs controls.
Our data show that both unipolar and bipolar depressed patients with psychotic features have significantly lower levels of platelet RI and higher levels of C subunits than healthy subjects, whereas the levels of RII were higher in unipolar patients with psychotic depression. Also bipolar patients showed an increase in the levels of RII, albeit this change did not reach statistical significance. Although future research is needed to ensure the involvement of this modification, our observation joined to previous studies point to differences between patients with unipolar and bipolar psychotic major depression. 14 As discussed in previous studies, [7] [8] [9] great care is necessary in interpreting data coming from peripheral cells since they are exposed to a different neurohormonal environment than that of brain tissue. The results presented in this article are generally consistent with early studies; however, it must be noted that PKA is differentially altered in psychotic and nonpsychotic patients with major depressed unipolar and bipolar disorder. [7] [8] [9] Results from a variety of clinical, experimental and naturalistic paradigms suggest that depression with psychotic features represents a distinct clinical entity rather than a severe subtype of depression.
14,17 From a biological point of view, several studies reported significant differences between patients with psychotic and nonpsychotic depression in the hypothalamicpituitary-adrenal (HPA) axis, dopamine ␤-hydroxylase activity, levels of dopamine and serotonin metabolites, sleep measures, and ventricle-to-brain ratios. [12] [13] [14] [15] [16] Interestingly, also the biochemical picture emerged on Rap1 is somewhat different between psychotic and nonpsychotic patients with major depressive episode. In fact, while previous studies reported that depressed unipolar and bipolar patients have lower and higher levels of Rap1 respectively, 7-9 the immunolabeling of this protein was unchanged in psychotic major depressed unipolar and bipolar patients. Although further replication of these data is warranted, these results allow us to speculate that Rap1 may be considered as a bio-chemical marker to distinguish nonpsychotic and psychotic depression.
Taken together, our data suggest that psychotic and nonpsychotic major depressed unipolar and bipolar patients may have distinctive biochemical dysfunctions of the cAMP pathway. This interpretation however must be replicated by independent studies before it can be fully accepted.
We ruled out the possibility that the altered PKA levels are caused simply by unspecific variables or effects on platelet proteins, because the levels of Rap1 and actin, a cytoskeletal protein used as internal control, did not differ among groups.
It has been reported that alterations in some components of cAMP signaling in affective patients may be treatment-related rather than disease related. 5 Thus, it is not so easy to exclude the role of a previous exposure to psychotropic medications in producing these changes, even though patients included in this study had been medication free for at least 1 month.
Considering early data reporting that PKA is altered by psychotropic medications, 1,2,18 it will be of interest to test whether antidepressant alone or in combination with antipsychotics could elicit normalization of PKA in depressed patients with psychotic features. Such an investigation might suggest a possible explanation for the clinical observation that the duration, dose, and response rate of pharmacological treatments differ in nonpsychotic and psychotic depressed patients. 14, 17, 19 The mechanism(s) underlying the alterations of PKA and whether they reflect a primary condition or a secondary response to neurohormonal perturbations remain still unclear. The lack of evidence in the literature regarding signal transduction in psychotic depression makes it difficult to directly compare how the alterations herein reported could relate to abnormal signal transduction in the brain. Nevertheless, our data are in line with a large number of previous studies showing abnormalities of the cAMP signaling pathway in postmortem brains of patients with psychiatric disorders. [1] [2] [3] [4] [5] [6] Our results may be associated with alterations in the HPA axis, reported in patients with psychotic depression. [14] [15] [16] This possibility is supported by recent studies showing that adrenal glucocorticoids modulate the levels and the activity of PKA. 20 Alternatively, the observed modifications may be ascribed to altered circulating levels of monoamines and metabolites. 14 Another possibility is that the altered levels of PKA may reflect adaptive responses to other dysfunctions in signal transduction such as Ca 2+ signaling and the phosphoinositides cycle, including protein kinase C. 2, 21, 22 In this regard, it is interesting to note that components of the phosphoinositide cycle, such as phospholipase C and protein kinase C, could also be regulated by administration of dexamethasone. 23, 24 Viewed in this light, the abnormal levels of PKA in psychotic depression may be attributed to the above mentioned observations, but at present, it is difficult to envisage the molecular mechanism(s) by which these modifications occur.
We are aware that more studies are needed to elucidate the functional significance of our findings. Nevertheless, given the critical role of PKA in the regulation of motor and emotive behavior, memory, stress and also in the action of psychotropic medications, the results we report may contribute to explain some of the clinical and pharmacological features of psychotic depression. 1, 2, 18, 25, 26 In conclusion, we found that the levels of PKA are altered in depressed patients with psychotic features. This study adds to the growing evidence suggesting that affective disorders with or without psychotic features might be associated with distinctive biochemical alterations of the cAMP signaling pathway. Future studies should provide new insights on the complex relationship between mood and psychosis.
Materials and methods
Subjects
Patients, admitted to the Mood Disorders Clinical and Research Unit, San Raffaele Hospital (Milan), who met the full DSM-IV criteria 11 for major depressive episode with psychotic features were recruited. Those with a history of important acute or chronic medical illness, or alcohol or psychotropic drug abuse were excluded from the study. Lifetime diagnoses were assigned by trained psychiatrists and supervised by an independent senior psychiatrist on the basis of unstructured clinical interviews and medical records, according to DSM-IV criteria 11 and following a best estimated procedure. 27 Clinical information was collected directly from each patient and from at least one close relative as a coinformant. Medical health was documented by the medical history, physical examination, electrocardiography, blood and serum chemical analyses (including hepatic and renal profiles), and thyroid function tests. The severity of symptomatology was evaluated using the global score of the 21-item Hamilton Rating Scale for Depression 28 (HRSD) and the delusion factor (items 2, 15, 20) . [28] [29] [30] The HRSD was administered by trained psychiatrists, who had a good inter-rater reliability. After providing written informed consent, 37 inpatients (16 unipolars, 6 male and 10 female, mean age 46.9 ± 13.6 years; and 21 bipolars, 8 male and 13 female, mean age 46.8 ± 14.1 years) were included in this study. The mean baseline HRSD score was 33.29 ± 4.2. The mean ± SD duration of the index depressive episode was 4.2 ± 1.3 weeks. The mean age at onset was 34.6 ± 10.3 years. Patients had been free of all medications for at least 1 month before blood specimens were drawn. The comparison group included 29 age-and-sex comparable healthy consenting volunteers (10 male and 19 female; mean age 45.6 ± 10.6 years), who had no personal or familial history of mental disorders, alcoholism, or drug abuse and no active medical problems, as determined by clinical interview. To exclude the presence of a personal or familial history of mental disorders, the proband and, when possible, other members of the proband's family or social group were interviewed. The healthy subjects had been free of all medications for at least 3 months before entering the study. None of the subjects took part in previous studies.
Platelets isolation and immunoblot analysis
A morning blood specimen was obtained from healthy volunteers and depressed patients by venipuncture and placed in tubes containing sodium citrate as anticoagulant. Platelets were isolated, prepared and then analyzed by personnel unaware of the diagnosis as previously described. [7] [8] [9] Aliquots with an equal platelet of proteins (5 g) were loaded on 12% polyacrylamide gels and subjected to 1-dimensional electrophoresis (sodium-dodecyl sulfate polyacrylamide gel electrophoresis). Patients' specimens were always run in duplicate or triplicate on the same gel with those of their respective controls. Proteins, thus resolved in bands, were electrophoretically transferred onto Hybond polyvinylidene difluoride membrane as described elsewhere. [7] [8] [9] After a thorough washing with TBS-T, the blots were incubated in blocking buffer for 90 min with monoclonal antibodies against the R type I (RI) (Transduction Laboratories, Lexington, KY, USA; dilution 1:500), the R type II (RII) (Biomol, Plymouth Meeting, PA, USA; dilution 1:2000), and the catalytic (C) (Transduction Laboratories; dilution 1:500) subunits of PKA, Rap1 (Transduction Laboratories; dilution 1:2500), and actin (clone DC40, Sigma-Aldrich Corp, St Louis, MO, USA, dilution 1:3500). After being extensively washed with TBS-T, the blots were incubated with the second antibody, horseradish peroxidase-linked antimouse (Sigma-Aldrich Corp; dilution 1:1000), in blocking buffer for 1 h. The labeled blots were then washed with TBS-T and immunoreactivity was detected with the Western blot detection system (Enhanced Chemiluminescent, Amersham Pharmacia Biotech, Little Chalfont, Bucks, UK), followed by exposure to film. Quantitation of the immunoblots was performed by densitometric scanning of the autoradiograms using an image analysis system (National Institute of Health Image, version 1.47, Bethesda, MD, USA). An aliquot of pooled standard platelet proteins was run on one lane of every gel to minimize the inter-assay variation, as previously described. [7] [8] [9] The optical density units obtained from each subject were normalized against those from a pooled platelet standard.
Statistical analysis
Data were analyzed using a one-way analysis of variance (ANOVA 2-tailed) followed by Newman-Keuls post hoc comparison tests. Results are expressed as means ± SD. The level of significance was P Ͻ 0.05.
